Business
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates that the initial closing of the.
About this update from Sharp Therapeutics Corp.
[{"type":"text","content":"Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates that the initial closing of the Note Offering will occur on or about February 12, 2026 (or such other date as may be determined by the Company), with subsequent closings to occur thereafter on such dates as may be determined by the Company (each, a "Closing Date"). The net proceeds of the Note Offering will be used for general working capital purposes.","length":872,"tagName":"p"},{"type":"text","content":"Each Note shall be convertible at the option of the holder into common shares in the capital of the Company (each, a "Conversion Share") at a conversion price of US$2.00 per Conversion Share (the "Conversion Price"), at any time prior to the date that is twelve (12) months following the applicable Closing Date (the "Maturity Date").","length":364,"tagName":"p"},{"type":"text","content":"Each Note shall bear interest at a rate of six percent (6.0%) per annum, calculated as simple interest accrued monthly in arrears. Interest on the principal amount outstanding under each Note shall accrue during the period commencing on the Closing Date and shall be payable by the Company in cash on the Maturity Date.","length":319,"tagName":"p"},{"type":"text","content":"Prior to the Maturity Date of the Notes, and only upon the completion by the Company of an equity financing with aggregate proceeds to the Company of at least US$7,000,000 (exclusive of any conversion proceeds from the Notes), the Company shall convert all of the outstanding principal amount of the Notes into Conversion Shares at the Conversion Price, upon giving the holders of the Notes not less than twenty (20) calendar days advance written notice. Any interest accrued and outstanding on the Notes at the time of such conversion shall be payable by the Company in cash.","length":576,"tagName":"p"},{"type":"text","content":"STX Partners, L...